- AVEO Pharmaceuticals believes that they are off to a strong start. It looks as if the first full quarter of FOTIVDA sales show there was some demand at launch.
- I am remaining cautiously optimistic about FOTIVDA’s launch and expect the Street to be skeptical about Aveo's commercial prospects in the coming quarters.
- I will discuss why I remain patient and wait for a couple more quarters of earnings and wait for the COVID headwinds to subside before getting overly bullish again.
- I attempt to reveal my current “buy” threshold.
For further details see:
AVEO Pharmaceuticals: Sticking To The Plan